Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 401–500 of 770
Kakiyama, G., Bai-Kamara, N., Rodríguez‐Agudo, D., Takei, H., Minowa, K., Fuchs, M. A., Biddinger, S. B., Windle, J. J., Subler, M. A., Murai, T., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100757 · Cited by 10
TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study
Huang, X., Hu, Y., Dong, L., Zhu, L., Li, J., Hu, J., Shao, W., Peng, Y., & Liu, F. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04087-4 · Cited by 10
Role of natural compounds in non-alcoholic fatty liver diseases (NAFLD): a mechanistic approach
Wal, P., Yadav, S., Jha, S. K., Singh, A., Bhargavi, B., Shivaram, R., Imran, M., & Aziz, N. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00452-w · Cited by 12
Insulin resistance: mechanisms and therapeutic interventions
Yu, L., Qian, J., Li, X., Tian, M., Bai, X., Yang, J., Deng, R., Lu, C., He, X., Lü, A., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00408-5 · Cited by 14
“A notable negative correlation is observed between the rate of DNL and insulin sensitivity [136].”
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 12
Peng, C., Ker, Y.-B., Li, H., Tsou, S., Lin, C., & Huang, C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265444 · Cited by 9
Association between de novo lipogenesis susceptibility genes and coronary artery disease
Simons, P. I. H. G., Valkenburg, O., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.09.003 · Cited by 8
Zhao, T., Zheng, H., Xu, J., Xu, Y.-C., Liu, L.-L., & Luo, Z. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122416 · Cited by 10
Shinde, S., Nelson, D. R., Mitroi, J., Heaton, P. C., Hincapie, A. L., & Brouwers, B. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2279676 · Cited by 12
“People with T2D are characterized by dysfunctional adipose tissue due to low-grade inflammation and adipose tissue insulin resistance 28–30 , leading to hepatic steatosis 31 .”
BackgroundWhat Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?
Ferenc, K., Jarmakiewicz-Czaja, S., & Filip, R. (2023) · Life · doi:10.3390/life14010037 · Cited by 10
“Given these mechanisms, analyses confirm that low physical activity is associated with a higher risk of NAFLD [118,154].”
BackgroundGiannotti, L., Stanca, E., Stanca, B. D. C., Spedicato, F., Massaro, M., Quarta, S., Rio, D. D., Mena, P. R., Siculella, L., & Damiano, F. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400338 · Cited by 9
Protein Targeting to Glycogen (PTG): A Promising Player in Glucose and Lipid Metabolism
Deng, X., Wang, C., Xia, Y., & Yuan, G. (2022) · Biomolecules · doi:10.3390/biom12121755 · Cited by 10
Mitochondrial control of glycerolipid synthesis by a PEP shuttle
Yamamuro, T., Katoh, D., Silva, G. M., Nishida, H., Oikawa, S., Higuchi, Y., Wang, D., Fujimoto, M., Yoshida, N., Li, M., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.017 · Cited by 11
Bianco, A., Franco, I., Curci, R., Bonfiglio, C., Campanella, A., Mirizzi, A., Fucilli, F., Giovanni, G. D., Giampaolo, N., Pesole, P. L., et al. (2023) · Nutrients · doi:10.3390/nu15102252 · Cited by 8
“However, insulin resistance (IR) seems to be one of the common denominators of both disorders [6,7].”
BackgroundYao, K., Chen, Z., Zhou, W., Liu, Z., & Cui, W. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102798 · Cited by 13
“These processes contribute to the development of steatosis in individuals with NAFLD (Smith et al., 2020).”
BackgroundChen, S., Wu, K., Ke, Y., Chen, S., He, R., Zhang, Q., Shen, C., Li, Q., Ruan, Y., Zhu, Y., et al. (2024) · Medicine · doi:10.1097/md.0000000000039613 · Cited by 8
Suryaningtyas, I. T., & Je, J. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102630 · Cited by 8
Elfaki, I., Mir, R., Elnageeb, M. E., Hamadi, A., Alharbi, Z. M., Bedaiwi, R. I., Javid, J., Alrasheed, T., Alatawi, D., Alrohaf, B. M., et al. (2025) · Medicina · doi:10.3390/medicina61010083 · Cited by 11
“Loss of weight reduces the triacylglycerol in liver cells [45,46].”
Li, Q.-H., & Xiang, J. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-90419-z · Cited by 8
“Previous studies have revealed that DNL is increased in patients with NAFLD, leading to lipid deposition in the liver, indicating that it may be a target to treat NAFLD 17,18 .”
Liu, W., Sun, M. J., Zhang, H., Wang, W., Song, J., Wang, M.-Y., Wang, C., & Sun, H.-M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141660 · Cited by 15
Mayengbam, S., Raman, M., Parnell, J. A., Eksteen, B., Lambert, J. E., Eller, L. K., Nicolucci, A. C., Aktary, M. L., & Reimer, R. A. (2025) · European Journal of Nutrition · doi:10.1007/s00394-025-03660-7 · Cited by 12
“Based on the literature [37, 38], diet-induced weight loss was expected to significantly reduce our primary outcome of intrahepatic fat, however, the modest reduction observed in our participants was lower than anticipated.”
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Aflatoxin Exposure in Immunocompromised Patients: Current State and Future Perspectives
Fagbohun, T. R., Nji, Q. N., Okechukwu, V. O., Adelusi, O. A., Nyathi, L. A., Awafong, P. M., & Njobeh, P. B. (2025) · Toxins · doi:10.3390/toxins17080414 · Cited by 14
Uddandrao, V. V. S., Krishna, D., Vasantha, M. N., Jayashree, G., Roy, A., Ravikkumar, V. R., Sengottuvelu, S., Chandrasekaran, P., Kathirvelan, C., Naidu, P. B., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2025.159682 · Cited by 8
Genomic medicine in hepatology: mechanisms and liver treatment strategies
Kozlov, D., Rodimova, S. A., Filatov, P. V., Mozherov, A. M., Timashev, P. S., Zyuzin, M. V., & Kuznetsova, D. S. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01358-4 · Cited by 11
Okue, S., Ishikawa, E., Nakahara, R., Ito, T., Okura, T., Sakae, M., Miura, A., Ozaki‐Masuzawa, Y., Hosono, T., & Seki, T. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaa038 · Cited by 9
Stierwalt, H. D., Morris, E. M., Maurer, A., Apte, U. M., Phillips, K., Li, T., Meers, G. M.-E., Koch, L. G., Britton, S. L., Graf, G., et al. (2022) · Physiological Reports · doi:10.14814/phy2.15405 · Cited by 8
Glucocorticoid therapy is a risk factor for cardiovascular diseases
Dzherieva, I. S., Волкова, Н. И., Davidenko, I. Y., Reshetnikov, I., Brovkina, S. S., Avakova, S. M., & Tishchenko, Y. V. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-3-93-106 · Cited by 12
MPEP Attenuates Intrahepatic Fat Accumulation in Obese Mice
Ferrigno, A., Cagna, M., Bosco, O., Trucchi, M., Berardo, C., Nicoletti, F., Vairetti, M., & Pasqua, L. G. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076076 · Cited by 9
“Insulin resistance is considered to be one of the key factors involved in the increase in hepatic DNL and in the release of adipokines and inflammatory cytokines, leading to NAFLD and NASH [36,37].”
BackgroundAxelrod, C. L., Langohr, I. M., Dantas, W. S., Heintz, E. C., Vandanmagsar, B., Yang, S., Zunica, E. R. M., Townsend, R. L., Albaugh, V. L., Berthoud, H., et al. (2023) · Obesity · doi:10.1002/oby.23876 · Cited by 10
“Obesity also drives de novo synthesis of intrahepatic triglycerides, which proceeds in a less controlled manner with increasing insulin resistance [20].”
Background7‐Hydroxyflavone improves nonalcoholic fatty liver disease by acting on STK24
Qi, X., Zhang, Y., Liao, Q., Xiao, Y., Jiang, T., Liu, S., Zhou, L., & Li, Y. (2024) · Phytotherapy Research · doi:10.1002/ptr.8207 · Cited by 9
“Glucose metabolism is tightly regulated by insulin (Norton et al., 2022), and hepatic lipid accumulation is closely associated with impaired insulin sensitivity (Smith et al., 2020).”
El‐Ashmawy, N. E., Khedr, E. G., Al‐Ashmawy, G. M., & Kamel, A. A. (2024) · Nutrition · doi:10.1016/j.nut.2024.112517 · Cited by 8
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Alfawaz, S. A., Burzangi, A. S., & Esmat, A. (2024) · Cureus · doi:10.7759/cureus.67080 · Cited by 16
Han, T., Li, Y., Xiao, J., Gong, H., Deng, F., Jiang, W., Wang, C., Chen, F., Zhang, C., Deng, J., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s469398 · Cited by 9
“24,25 Currently, the long-term CVD risk of lean NAFLD and its pathophysiology have not received enough attention and in-depth research.”
BackgroundThe Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)
Venniyoor, A., Farsi, A. M. A., & Bahrani, B. J. A. (2021) · Cureus · doi:10.7759/cureus.17320 · Cited by 11
“Few authors believe that insulin resistance causes NAFLD [25,26] while many suggest that NAFLD leads to insulin resistance and hyperinsulinemia [27,28].”
BackgroundA short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)
Roberts, S. K., & Majeed, A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1999416 · Cited by 9
Batista, E. S., Rios, T. D. S., Muñoz, V. R., de Jesus, J. S., Vasconcelos, M. M., da Cunha, D. T., Marques-Rocha, J. L., Nakandakari, S. C. B. R., Lara, R., da Silva, A. S. R., et al. (2021) · Trials · doi:10.1186/s13063-021-05702-x · Cited by 9
“content in capsules or fish’s flesh, [33] [2] uncontrolled bioavailability from gut to the bloodstream and bioaccessibility from the blood to cell incorporation/uptake, [3] ω3 discrepant doses [4], [4] ω3 EPA: DHA blend, [5] incorrect placebo choices [34, 35], and [6] the presence of GPR120 polymorphism [36].”
BackgroundIntrahepatic triglyceride content: influence of metabolic and genetics drivers
Dearlove, D., & Hodson, L. (2022) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000838 · Cited by 10
Gignac, T., Trépanier, G., Pradeau, M., Morissette, A., Agrinier, A.-L., Larose, É., Marois, J., Pilon, G., Gagnon, C., Vohl, M., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00294.2023 · Cited by 8
Exploring the impact of lipid droplets on the evolution and progress of hepatocarcinoma
Maurotti, S., Geirola, N., Frosina, M., Mirarchi, A., Scionti, F., Mare, R., Montalcini, T., Pujia, A., & Tirinato, L. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1404006 · Cited by 9
Khan, M. M., Khan, Z. A., & Khan, M. A. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i6.767 · Cited by 7
Buziau, A. M., Oosterveer, M. H., Wouters, K., Bos, T., Tolan, D. R., Agius, L., Ford, B. E., Cassiman, D. M., Stehouwer, C. D. A., Schalkwijk, C. G., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101984 · Cited by 8
Li, Z., Liu, R., Gao, X., Hou, D., Leng, M., Zhang, Y., Du, M., Zhang, S., & Li, C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01399-5 · Cited by 11
“Then IR further contributes to hepatic de novo lipogenesis and deposition of ectopic fat [9].”
BackgroundMa, C., Yang, X., Zhang, L., Zhang, J., Zhang, Y., & Hu, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318696 · Cited by 7
“Insulin resistance enhances the gluconeogenesis process in the liver and also promotes the synthesis of triglycerides [1] and fat [16,10].”
Liu, S., Duan, J.-H., Chen, Y., Gu, S.-L., Yu-hua, H., Xue, M.-M., & Yue, J.-Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1555300 · Cited by 9
Chen, Q.-C., Cai, W., Ni, Q., Lin, S., Jiang, C., Yi, Y., Liu, L., Liu, Q., & Shen, C. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01793-7 · Cited by 7
“…in the liver is often associated with elevated insulin levels, which drives the activation of the core hepatic DNL drivers, SREBP-1c and ChREBP, and reduces fatty acid breakdown by inhibiting fatty acid β -oxidation, especially in the presence of a high-sugar diet and insulin resistance [86].”
Chen, Y., Lin, X., Chen, Y., Wang, B., Xu, C., & Wang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1626672 · Cited by 9
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
Noninvasive NMR/MRS Metabolic Parameters to Evaluate Metabolic Syndrome in Rats
Htun, K. T., Jaikumkao, K., Pan, J., Moe, A. T. M., Intachai, N., Promsan, S., Lungkaphin, A., Tapanya, M., Pasanta, D., Tungjai, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12071621 · Cited by 7
“Indeed, the interaction between highly metabolically active visceral fat and an accelerated rate of de novo lipogenesis in hepatic steatosis may enhance the loss of hepatic insulin sensitivity and is the major cause of hyperglycemia [8,9].”
BackgroundAntidiabetic Effect of Bifidobacterium animalis TISTR 2591 in a Rat Model of Type 2 Diabetes
Hanchang, W., Dissook, S., Wongmanee, N., Rojanaverawong, W., Charoenphon, N., Pakaew, K., Sitdhipol, J., Thanagornyothin, T., Phapugrangkul, P., Ayudthaya, S. P. N., et al. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10377-2 · Cited by 8
“Studies in both animal and clinical research have reported an upregulation of lipid synthesis and excessive hepatic lipid accumulation in diabetes [44, 45].”
Shokri, B., Mohebbi, H., & Mehrabani, J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02347-y · Cited by 7
“Insulin further promotes the transcription of genes necessary for fatty acid synthesis [43], thereby establishing a positive feedback loop where insulin resistance enhances hepatic DNL and where hepatic DNL exacerbates insulin resistance [44].”
BackgroundBiomimetic Cell Membrane Layers for the Detection of Insulin and Glucagon
Nandhakumar, P., Sun, L., Li, Z., Cheung, C., Nguyen, L., Ding, S., Gao, W., Zhang, L., & Wang, J. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05347 · Cited by 7
Xu, M., Gong, R., Xie, J., Xu, S., & Wang, S. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00927-y · Cited by 13
“This metabolic milieu is further compounded by bile acid dysmetabolism and cholestasis, manifesting as elevated alkaline phosphatase (ALP) and GGT [67].”
The effect of acute and chronic exercise on hepatic lipid composition
Willis, S. A., Malaikah, S., Parry, S. A., Bawden, S., Ennequin, G., Sargeant, J. A., Yates, T. E., Webb, D. R., Davies, M. J., Stensel, D. J., et al. (2023) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.14310 · Cited by 7
NOD1 activation in 3T3-L1 adipocytes confers lipid accumulation in HepG2 cells
Gulzar, F., Ahmad, S., Singh, S., Kumar, P., Sharma, A., & Tamrakar, A. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121400 · Cited by 7
Complex regulation of fatty liver disease
Ginsberg, H. N., & Mani, A. (2022) · Science · doi:10.1126/science.abp8276 · Cited by 7
Wu, Y., Yang, M., Wu, S., Luo, P.-Q., Zhang, C., Ruan, C.-S., Cui, W., Zhao, Q.-R., Chen, L., Meng, J.-J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06224-2 · Cited by 7
“DNL has been found to be one of the predominant contributors to the development of hepatic steatosis [6, 7].”
Smith, K., Taylor, G., Peeters, W., Walker, M., Perazzolo, S., Atabaki‐Pasdar, N., Davies, K. A. B., Karpe, F., Hodson, L., Stevenson, E., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06249-7 · Cited by 6
“…for the pathophysiology of hepatic steatosis that is described by increased plasma glucagon concentrations [29] and increased hepatic lipid flux [45]; these ‘dual-hit’ signals may offer an explanation as to why CEACAM1 expression [46] and ICR [8, 31] are reduced in people with increased liver…”
BackgroundSaturated Fats: Time to Assess Their Beneficial Role in a Healthful Diet
Lawrence, G. D. (2024) · Dietetics · doi:10.3390/dietetics3040033 · Cited by 7
Cai, X., Li, W., Wang, L., Shi, Y., Gao, J., Wang, H., Lei, T., & Lu, J. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01768-1 · Cited by 7
“…target of rapamycin complex 1 (mTORC1) and subsequent ribosomal protein S6 kinase, thus resulting in decreased insulin-induced phosphoinositide 3-kinase activity and subsequently impaired insulin signaling [32], on the other hand, insulin resistance could further accelerate lipogenesis [33].”
BackgroundHu-lu-su-pian ameliorates hepatic steatosis by regulating CIDEA expression in AKT-driven MASLD mice
Ren, R., Wang, Q., Deng, D., Guo, A., Chen, X., Meng, Y., Ying, F., Zheng, G., Xu, Z., Li, M., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1503247 · Cited by 6
Aiello, C., Felli, É., Musarra, T., Nevi, L., Altomare, A., Gracia‐Sancho, J., Baiocchini, A., & Carotti, S. (2025) · International Journal of Cancer · doi:10.1002/ijc.70047 · Cited by 8
“39 In MASLD and HCC, DNL is controlled by mammalian target of rapamycin (mTOR), ChREBP, and SREBP1-c that, through acetyl-CoA carboxylase (ACC), stearoyl-CoA desaturase 1 (SCD1), and ATP citrate lyase (ACLY), sustain lipid synthesis.”
Hamad, R. S., Hasan, W. A., Elmorsy, E. A., Farrag, A. A. M., Abdelaziz, M. A., Alalawy, A. I., Parveen, H., Mukhtar, S., Alsirhani, A. M., ALrashidi, A. A., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115852 · Cited by 6
Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance
Tao, R., Stöhr, O., Tok, O., Andrés-Hernando, A., Qiu, W., He, B., Wang, C., Grøntved, L., Burant, C., Hui, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66296-5 · Cited by 7
“Esteri fi cation of circulating FFA released through adipose lipolysis contributes signi fi cantly to intrahepatic TAG accumulation in MASLD patients 48,81 .”
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
“In turn, the chronic hyperglycemia and compensatory hyperinsulinemia characteristic of diabetes exacerbate hepatic de novo lipogenesis and lipid deposition, thereby perpetuating a vicious cycle [7,33].”
Cho, W., Oh, H., El‐Aty, A. M. A., Özten, Ö., Jeong, J. H., & Jung, T. W. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149671 · Cited by 6
Sun, Z., Wei, Y., Xu, Y., Jiao, J., & Duan, X. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100475 · Cited by 7
Li, Z., Jin, Y., Zhao, H.-S., Gu, Y., Zhang, Y., Cheng, S., Zhang, L., He, P., Liu, X., & Jia, Y. (2025) · Phytotherapy Research · doi:10.1002/ptr.8459 · Cited by 7
“Hyperglycemia and hyperlipidemia stimulate hepatic DNL, converting carbohydrates into fatty acids (Smith et al. 2020), with hepatic DNL being significantly higher in patients with than without NAFLD (Lambert, Ramos-Roman, Browning, & Parks, Lambert et al. 2014).”
Function of PNPLA3 I148M —Lessons From In Vivo Studies in Humans
Yki‐Järvinen, H., & Luukkonen, P. K. (2025) · Liver International · doi:10.1111/liv.70047 · Cited by 8
Parry, S. A., Rosqvist, F., Peters, S., Young, R. K., Cornfield, T., Dyson, P. A., & Hodson, L. (2021) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v126.7649 · Cited by 7
“For instance, individuals with metabolic-associated fatty liver disease (MAFLD) demonstrate increased de novo lipogenesis (DNL) relative to their non-MAFLD counterparts (42), which may lead to an increased palmitate abundance in plasma lipid fractions.”
BackgroundHuang, G., Zhou, H., Shen, C., Sheng, Y., Xue, R., Dong, C., & Zhang, S. (2021) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.1960364 · Cited by 7
“Moreover, when hepatic insulin resistance occurs, triglycerides begin to accumulate in the liver, finally resulting in liver disease and elevated ALT presents (36,37).”
BackgroundApproaches to Measuring the Activity of Major Lipolytic and Lipogenic Enzymes In Vitro and Ex Vivo
Wilhelm, M., Rossmeislová, L., & Šiklová, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911093 · Cited by 6
“In the liver, excessive DNL leads to hepatic steatosis linked with lower hepatic insulin sensitivity [19] but, in AT, DNL produces several insulin-sensitizing lipokines [20–22] and positively regulates adipocyte membrane fluidity”
BackgroundPredictive Risk Factors of Nonalcoholic Fatty Liver Disease in a Lean Chinese Population
Liu, L., Shi, X., Gao, J., Xu, C., & Liu, X. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121958 · Cited by 7
Tang, H., Ling, J., Meng, H., Wu, L., Zhu, L., & Zhu, S. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06508-3 · Cited by 7
Hodson, L., Parry, S. A., Cornfield, T., Charlton, C. A., Low, W. S., Green, C., & Rosqvist, F. (2020) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2020.1739789 · Cited by 6
Measurement of gluconeogenesis by 2H2O labeling and mass isotopomer distribution analysis
Ziari, N., & Hellerstein, M. K. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105206 · Cited by 7
Self-citationTian, Y., Gong, J., He, Z., Peng, S., Huan, Y., & Cao, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86596-6 · Cited by 8
Growth Hormone Promotes Hepatic Triglyceride Export in Humans
Baumgartner, C., Metz, M., Beghini, M., Pfleger, L., Tosin, A., Koldyka, O., Beiglböck, H., Fellinger, P., Vila, G., Luger, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf155 · Cited by 6
Wu, X., Jiacheng, M., Yu, J., Zhang, S. J., Zheng, D., Chen, X., Qi, R., Jiang, J., Ye, K., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1740308 · Cited by 5
“Insulin resistance (IR) is considered the core mechanism underlying the development of MASLD (8, 9).”
Metabolic flux analysis in adipose tissue reprogramming
Medina, A., Bruno, J., & Alemán, J. O. (2024) · Immunometabolism · doi:10.1097/in9.0000000000000039 · Cited by 6
“While flux analysis using alternative radioactive isotopes is uncommon, multiple groups including ours are developing methodologies for implementing 2 H and 18 O tracing in biologically relevant scenarios [37,40] .”
MethodHo, H.-T., Shih, Y., Huang, T., Fang, W., Liu, C.-H., Lin, J., Hsiang, C., Chu, K., Hsiong, C.-H., Chen, G.-J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05686-7 · Cited by 6
“Studies have elucidated that hepatic DNL, characterized by an abnormal increase in newly synthesized fatty acids in the liver, plays a pivotal role in the development of steatosis and the progression of MASLD [32, 33].”
BackgroundWang, W., Chen, Y., Tu, M., & Chen, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1384059 · Cited by 6
Mabuda, T. I., Sibuyi, N. R. S., Fadaka, A. O., Meyer, M., Madiehe, A. M., & Gabuza, K. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09980-7 · Cited by 6
Hou, J., Liu, Y., Deng, Z., Sun, J., & Zhao, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1078652 · Cited by 5
Korpimäki, S., Rovio, S., Juonala, M., Hutri‐Kähönen, N., Lehtimäki, T. J., Laitinen, T. P., Tossavainen, P. H., Jokinen, E. V., Loo, B.-M., Männistö, S., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad418 · Cited by 34
Buyl, K., Vrints, M., Fernando, R. N., Desmae, T., Eeckhoutte, T. V., Jans, M., van der Schueren, J., Boeckmans, J., Rodrigues, R. M., Boe, V. D., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175989 · Cited by 5
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 6
“Also, hepatic IR leads to an upregulation of de novo lipogenesis mainly through increased activity of the sterol regulatory element binding protein 1c (SREBP-1c), which contributes further to fat accrual in liver cells [28–32].”
Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway
Zeng, G., Liu, X., Zheng, Z., Zhao, J., Zhuo, W., Bai, Z., Lin, E., Cai, S., Cai, C., Li, P., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02419-z · Cited by 7
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Du, H., Huang, J., Wang, Y., Wang, C., Wang, Y., Hou, L., Li, Y., Li, Y., & Su, Q. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03732-2 · Cited by 7
“This process plays a pivotal role in fat accumulation, and insulin resistance is a major driver of hepatic DNL in MASLD [33].”
Doridot, L., Hannou, S. A., Krawczyk, S. A., Tong, W., Kim, M.-S., McElroy, G. S., Fowler, A. J., Astapova, I. I., & Herman, M. A. (2021) · Nutrients · doi:10.3390/nu13103642 · Cited by 5
“In humans and animal models, increased DNL is thought to be a significant contributor to the development of steatosis [49,50].”
BackgroundFructose intake enhances lipoteichoic acid-mediated immune response in monocytes of healthy humans
Staltner, R., Csarmann, K., Geyer, A., Nier, A., Baumann, A., & Bergheim, I. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103729 · Cited by 6
“This has been accounted primarily to an increased hepatic de novo lipogenesis and reduced fatty acid oxidation, which promote liver fat accumulation and insulin resistance [10].”
Mir, S. A., Narasimhan, K., Annadurai, J. K., Vaitheeswari, Ji, S., Cameron‐Smith, D., Eriksson, J. G., Leow, M. K., Wenk, M. R., Torta, F. T., et al. (2025) · Diabetes · doi:10.2337/db25-0010 · Cited by 6
Zhou, Z., Gao, N., Liu, J., Ma, X., Ge, Z., & Cheng, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70168 · Cited by 8
“8,9 Moreover, glucotoxicity caused by chronically elevated plasma glucose can exacerbate the metabolic milieu deterioration via β -cell dysfunction and aggravate hepatocellular injury through oxidative stress and inflammatory responses.”
Sirtuin 6 activator UBCS039 ameliorates hepatic lipogenesis through liver X receptor deacetylation
Cho, Y. E., Kim, Y. S., Jo, H., Lim, H., Kim, S., Lee, H., & Hwang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115878 · Cited by 6
Ge, Y., Deng, S., Zhang, X., Liu, H., Chen, Y., Liu, Y., Liu, S., Fu, H., Yang, Y., & Wu, Z. (2025) · Food & Function · doi:10.1039/d4fo01605j · Cited by 4
Ren, J., Jiang, T., Wei, X., Bian, T., Xu, M., Zhao, Y., Zheng, Y., & Li, X. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70118 · Cited by 5
“This lipogenic drive is further augmented by hyperglycemia‐induced activation of ChREBP [21].”
Integrative multi-omics analysis reveals oral microbiome-metabolome signatures of obesity
Shibl, A. A., Denekew, T. W., Ahmad, A. R., Abdelrazig, S., Leonor, C., Utenova, L., Zhang, G., AbdelBaqi, M., Malla, Y., Arshad, M., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116819 · Cited by 9
Siani, M., Bonfiglio, C., Bonfrate, L., Donghia, R., & Pastore, M. N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1797230 · Cited by 5
“De novo lipidic lipogenesis (DNL) appears to be the primary contributor to TG accumulation in MASLD patients (8).”
Petersen, M. C., Smith, G. I., Farabi, S. S., Palacios, H. H., Shankaran, M., Hellerstein, M. K., Patterson, B. W., & Klein, S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.020 · Cited by 7
Self-citationLi, Y. T., Pan, T., Wang, Y., Wang, G., & Wang, F. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.041 · Cited by 5
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.